Glossary
The terms on pricing pages and pharmacy disclosures, defined.
Released: · Last reviewed:
The terms on pricing pages and pharmacy disclosures, defined.
Terms used on pricing and pharmacy pages
- All-in monthly cost
- Medication plus any recurring membership or platform fee, at a named dose.
- 503A pharmacy
- A pharmacy compounding for an identified patient against a valid prescription.
- 503B outsourcing facility
- A federally registered facility compounding at larger scale under FDA oversight.
- Beyond-use date
- The date after which a compounded preparation should not be used. Shorter than an expiry date.
- Certificate of analysis
- A lot-specific document reporting identity, purity and potency testing.
- Cost per milligram
- All-in monthly cost divided by milligrams of active drug delivered that month.
- Dose-scaled pricing
- A price that rises as the prescribed dose increases.
- Flat pricing
- One price at every dose tier.
- First-year cost
- Two months of titration plus ten at a maintenance dose, on one model.
- Membership fee
- A recurring platform charge billed separately from medication.
- Prepaid term
- A multi-month commitment billed up front, usually at a discount, usually non-refundable once shipped.
- Promotional rate
- A discounted first period that reverts to a standing rate.
- Evidence status
- Whether we read a price at the provider, took it from a third party, or could not obtain one.
- Titration
- The stepped increase from a starter dose to a maintenance dose, at least four weeks per step.
- Non-resident pharmacy licence
- Permission for a pharmacy to ship into a state where it is not located.
What this page covers
The terms on pricing pages and pharmacy disclosures, defined. Everything on this site rests on one dataset with a capture date and an evidence status on every record, so this page explains a rule rather than an opinion.
The standard we hold ourselves to
Publish what can be verified, label what cannot, and say plainly when a figure has changed. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before marketing; every page that touches price says so.
How to check us
The dataset behind every table is downloadable, every ranking states its sort key, and every programme page links to that programme's own pricing page. If our figure and theirs differ, ours is wrong and we want to know.
How this site works
Every price on this site is read on the program’s own pages and carries its read date. Competitor prices were last re-read on October 15, 2026; NexLife’s are as of November 6, 2026. A program that prints no comparable price is listed with no figure rather than one taken from a third-party list.
Tirzepatide Telehealth Comparison is affiliate-supported and may earn a commission when readers enroll through links on this site. Compensation never changes our methodology, rankings or the prices we report. NexLife is our editorial pick on the v4.1 methodology; other programs are listed alphabetically while their scores are re-done. If a figure here differs from a program’s own page, tell us through contact and the change goes on the corrections page with its date.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.